Table 4.

Treatment related adverse events (TRAE) in the study population by treatment.

Variables	Nivolumab group (n = 32)		Regorafenib group (n = 58)
	Any, n (%)	Grade ≥ 3, n (%)	Any, n (%)	Grade ≥ 3, n (%)
Total patients with TRAE*	12 (37.5)	2 (6.2)	40 (68)	6 (10.2)
Hand foot skin reaction, n (%)	0	0	14 (23.8)	1 (1.7)
Diarrhea, n (%)	1 (3.1)	0	7 (11.9)	0
Fatigue, n (%)	4 (12.4)	0	6 (10.2)	2 (3.4)
Elevated AST, n (%)	0	0	6 (10.2)	0
Decreased appetite, n(%)	1(3.1)	0	4 (6.8)	0
Dermatitis, n (%)	3 (9.3)	0	4 (6.8)	0
Elevated T-bil, n (%)	2 (6.2)	2 (6.2)	4 (6.8)	3 (5.1)
Paresthesia, n (%)	1 (3.1)	0	0	0
Hypertension, n (%)	0	0	1 (1.7)	0
Hoarseness, n (%)	0	0	1 (1.7)	0
Pruritus, n (%)	0	0	1 (1.7)	0

AST, aspartate aminotransferase; T-bil, total bilirubin; TRAE, treatment related adverse event.

*The comparison of total patients with TRAE between two groups was significant different (p=0.006).